近年来，国家医保药品目录谈判成为创新药进入市场的关键环节。医保局今年在药品目录谈判中，重点考虑了创新药的发展趋势，以加快新药上市。此次谈判共有2000多种药品参与，其中不少是治疗癌症、罕见病等疾病的新药。
在谈判过程中，医保局与药企进行了充分沟通，就价格、疗效、安全性等进行了评估。最终，约200种创新药被列入医保目录，这将有助于降低患者负担，提高医疗质量。
此次谈判的亮点之一是，医保局加大了对罕见病药品的支持力度，将更多特效药纳入目录，以满足患者的个性化需求。此外，谈判还充分考虑了国内药品生产企业的利益，促进产业合理发展。
英文标题：National Health Insurance drug list negotiation accelerates approval of innovative drugs
关键词：National Health Insurance, drug list, negotiation, innovative drugs
新闻内容：
In recent years, the negotiation of the National Health Insurance drug list has become a key factor in the entry of innovative drugs into the market. The National Health Insurance Administration focused on the development trend of innovative drugs in this year’s drug list negotiation, in order to accelerate the entry of new drugs. This year, a total of more than 2,000 drugs participated in the negotiation, many of which are new drugs for treating cancer and rare diseases.
During the negotiation process, the National Health Insurance Administration and pharmaceutical companies thoroughly discussed price, efficacy, and safety. In the end, about 200 innovative drugs were added to the drug list, which will help reduce patients’ burden and improve medical quality.
One of the highlights of this negotiation is that the National Health Insurance Administration has increased its support for rare disease drugs, and more effective drugs are included in the list to meet the personalized needs of patients. In addition, the negotiation also fully considers the interests of domestic pharmaceutical manufacturers, promoting the rational development of the industry.
【来源】http://www.chinanews.com/cj/2023/12-23/10134248.shtml
Views: 1